Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Showing 1 to 12 of 150 entries
Sorted by: Best Match Show Resources per page
Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy.


Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA.
PMID: 1319075
Radiology. 1992 Jul;184(1):243-8. doi: 10.1148/radiology.184.1.1319075.

The ability of dynamic, gadolinium-enhanced magnetic resonance (MR) imaging to allow prediction of histologic responses to initial chemotherapy was evaluated in 20 patients with osteosarcoma (n = 12), Ewing sarcoma (n = 4), rhabdomyosarcoma (n = 3), or synovial...

Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital.


Hutchison RE, Murphy SB, Fairclough DL, Shuster JJ, Sullivan MP, Link MP, Donaldson SS, Berard CW.
PMID: 2731117
Cancer. 1989 Jul 01;64(1):23-8. doi: 10.1002/1097-0142(19890701)64:1<23::aid-cncr2820640105>;2-t.

The clinical relevance of a morphologic distinction between Burkitt's (B) and non-Burkitt's (NB) types of small non-cleaved cell (SNC) non-Hodgkin's lymphoma (NHL) has been controversial. Numerous attempts to discern an important clinical difference between the subtypes have failed to...

Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy.

International journal of radiation oncology, biology, physics

Arai Y, Kun LE, Brooks MT, Fairclough DL, Fontanesi J, Meyer WH, Hayes FA, Thompson E, Rao BN.
PMID: 1938559
Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1501-8. doi: 10.1016/0360-3016(91)90325-x.

Sixty children with localized osseous Ewing's sarcoma were treated between 1978 and 1988 with induction chemotherapy (cyclophosphamide, adriamycin), irradiation and/or surgery, and 10 months of maintenance chemotherapy (cyclophosphamide, adriamycin, dactinomycin, vincristine). Following induction chemotherapy, 43 patients received primary radiation...

Subtle neuropsychological deficits in children with sickle cell disease.

The American journal of pediatric hematology/oncology

Wasserman AL, Wilimas JA, Fairclough DL, Mulhern RK, Wang W.
PMID: 2029072
Am J Pediatr Hematol Oncol. 1991;13(1):14-20. doi: 10.1097/00043426-199121000-00004.

Forty-three children and adolescents (8-16 years old) with sickle cell disease (SCD) and no overt neurologic dysfunction were evaluated with the Wechsler Intelligence Scale for Children-Revised (WISC-R), the Wide Range Achievement Test (WRAT), and an age-appropriate version of the...

Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Kovnar EH, Kellie SJ, Horowitz ME, Sanford RA, Langston JW, Mulhern RK, Jenkins JJ, Douglass EC, Etcubanas EE, Fairclough DL.
PMID: 2153766
J Clin Oncol. 1990 Feb;8(2):330-6. doi: 10.1200/JCO.1990.8.2.330.

Medulloblastoma, pineoblastoma, and cerebral neuroblastoma are malignant embryonal tumors of the CNS that may demonstrate similar histologic features, a propensity for neuraxis dissemination and sensitivity to radiation therapy and, in certain cases, chemotherapy. To evaluate the activity of preirradiation...

A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors.


Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME.
PMID: 7743483
Cancer. 1995 Jun 01;75(11):2762-7. doi: 10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>;2-2.

BACKGROUND: Chemotherapy may be used to delay the need for cranial irradiation in infants and young children with malignant central nervous system (CNS) tumors. The polyfunctional alkylator thiotepa (TT) possesses significant in vitro and in vivo activity in many...

Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Fairclough DL, Cella DF.
PMID: 8763800
Qual Life Res. 1996 Jun;5(3):321-9. doi: 10.1007/BF00433916.

The purpose of this investigation is to examine methods of scoring the FACT-G when there is non-response to individual questions. Using completed questionnaires from 350 patients, random and non-random missing responses where simulated. Seven methods of scoring the FACT-G...

Understanding the experience of pain in terminally ill patients.

Lancet (London, England)

Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ.
PMID: 11343734
Lancet. 2001 Apr 28;357(9265):1311-5. doi: 10.1016/S0140-6736(00)04515-3.

BACKGROUND: Terminally ill patients commonly experience substantial pain. Unresolved pain has been cited as evidence that end-of-life care is of poor quality. However, the data on which that conclusion is based are limited. We aimed to provide additional data...

Statistical analysis of quality of life with missing data in cancer clinical trials.

Statistics in medicine

Troxel AB, Fairclough DL, Curran D, Hahn EA.
PMID: 9549814
Stat Med. 1998 Mar 15-Apr 15;17(5):653-66. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>;2-m.

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data...

Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers.


Emanuel EJ, Fairclough DL, Emanuel LL.
PMID: 11074775
JAMA. 2000 Nov 15;284(19):2460-8. doi: 10.1001/jama.284.19.2460.

CONTEXT: Euthanasia and physician-assisted suicide (PAS) are highly controversial issues. While there are studies of seriously ill patients' interest in euthanasia and PAS, there are no data on the attitudes and desires of terminally ill patients regarding these issues.OBJECTIVE:...

Planning analyses of quality-of-life studies: a case example with migraine prophylaxis.

Journal of biopharmaceutical statistics

Fairclough DL, Gagnon D, Papadopoulos G.
PMID: 15027499
J Biopharm Stat. 2004 Feb;14(1):31-51. doi: 10.1081/BIP-120028505.

Assessment of health-related quality of life (QOL) has become increasingly common in clinical trials. Because QOL has multiple dimensions and is assessed repeatedly over time, multiple comparisons and missing data must be addressed in the design and analysis of...

The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ, Cella D.
PMID: 15058795
Qual Life Res. 2004 Feb;13(1):137-54. doi: 10.1023/B:QURE.0000015297.91158.01.

PURPOSE: This paper reports on the development and validation of two biologic response modifier (BRM) subscales for use with the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life (QOL) questionnaire.METHODS: Using the FACT-G as a base, 17 additional...

Showing 1 to 12 of 150 entries